Who are Tenoretic 100's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Singulair, Adenocard, HALOPROGIN, Oxtriphylline, Dulcotil, Estrobene.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atenolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tenoretic 100 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenoretic 100 (ATENOLOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-Adrenergic Blocker [EPC]. Area: Neuroscience.

marketed beta-Adrenergic Blocker [EPC] Adenosine receptor A3 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Tenoretic 100 (ATENOLOL) — Twi Pharms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenoretic 100 TARGET	ATENOLOL	Twi Pharms	marketed	beta-Adrenergic Blocker [EPC]	Adenosine receptor A3	1981-01-01
Singulair	montelukast	Merck & Co.	marketed	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Adenocard	ADENOSINE	Astellas Pharma	marketed	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
HALOPROGIN	HALOPROGIN	Westwood Squibb	marketed	haloprogin	Adenosine receptor A3	1982-01-01
Oxtriphylline	choline theophyllinate	Warner Chilcott Llc	marketed	choline theophyllinate	Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1	1981-01-01
Dulcotil	SULOCTIDIL		marketed	suloctidil	Adenosine receptor A3, Substance-K receptor, 5-hydroxytryptamine receptor 1A	1979-01-01
Estrobene	DIETHYLSTILBESTROL	Tablicaps	marketed	Standardized Chemical Allergen [EPC]	Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta-Adrenergic Blocker [EPC] class)

· 1 drug in this class
Twi Pharms · 1 drug in this class
Uswm · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenoretic 100 — Competitive Intelligence Brief. https://druglandscape.com/ci/atenolol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing